Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health

Results from quantitative MRI and neuropsychological testing show unprecedented improvements in ten patients with early Alzheimer’s disease (AD) or its precursors following treatment with a programmatic and personalized therapy. Results from an approach dubbed metabolic enhancement for neurodegeneration are now available online in the journal Aging.

The study, which comes jointly from the Buck Institute for Research on Aging and the UCLA Easton Laboratories for Neurodegenerative Disease Research, is the first to objectively show that memory loss in patients can be reversed, and improvement sustained, using a complex, 36-point therapeutic personalized program that involves comprehensive changes in diet, brain stimulation, exercise, optimization of sleep, specific pharmaceuticals and vitamins, and multiple additional steps that affect brain chemistry.

“All of these patients had either well-defined mild cognitive impairment (MCI), subjective cognitive impairment (SCI) or had been diagnosed with AD before beginning the program,” said author Dale Bredesen, MD, a professor at the Buck Institute and professor at the Easton Laboratories for Neurodegenerative Disease Research at UCLA, who noted that patients who had had to discontinue work were able to return to work and those struggling at their jobs were able to improve their performance. “Follow up testing showed some of the patients going from abnormal to normal.”

Read more

It would seem that no one’s immune from the effects imposed by our increasingly sophisticated artificial intelligence and robotics — not even doctors. As research from Indiana University has revealed, a new computer program is doing a better job than doctors when it comes to both diagnosing and treating health conditions — and by a significant margin.

The system, which uses decision making processes similar to the Jeopardy-bot, Watson, was recently given the task of analyzing and predicting the health outcomes of 500 real individuals. After plugging in the relevant data — which mostly had to do with clinical depression and chronic diseases like high blood pressure and diabetes — researchers Kris Hauser and Casey Bennett compared the outcomes to the simulated treatment prescriptions.

Read more

A small clinical trial of 10 patients with early Alzheimer’s disease has shown that the memory loss and cognitive impairment caused by the disease can be reversed.

Scientists at the University of California, Los Angeles found a new treatment that could potentially reverse memory loss and cognitive impairment among patients with early Alzheimer’s disease.

In a small clinical trial, 10 individuals underwent a treatment called “metabolic enhancement for neurodegeneration,” or MEND. The treatment is based on 36 different factors, including changes in diet, exercise, and sleeping habits. It also includes the integration of certain drugs, vitamins, and brain stimulation therapy to a patient’s regular routine.

Read more

A new study found that higher concentrations of NAA (N-acetyl aspartate) in two areas of the brain were associated with better performance on verbal and spatial tests. NAA is a byproduct of glucose metabolism and an indicator of brain health. (credit: Julie McMahon and Erick Paul)

A new study helps explain how brain structure and chemistry relate to “fluid intelligence” — the ability to adapt to new situations and solve problems one has never encountered before.

The study, reported in an open-access paper in the journal NeuroImage, observed two facets of fluid intelligence*:

Read more

Excellent!!! Cannot wait until we eradicate cancer, MS, Parkinson, Dystonia, Cystic-Fibrosis, LGD, etc.

A team of Physicians at the University of Pennsylvania’s School of Medicine now has their project of modifying the immune cells of 18 different cancer patients with the CRISPR-Cas9 system approved by the National Institute of Health.

CRISPR is the gift that keeps on giving—when it’s not fighting blindness, tackling HIV, or even recording real-time immune responses, it is taking on the emperor of all maladies: cancer.

But what’s even more fascinating about this use of CRISPR is that the National Institute of Health’s (NIH) Recombinant DNA Research Advisory Committee (RAC) has approved the first-ever use of CRISPR in human cancer therapy, a monumental step in the history of the gene-editing technology.

Read more

Scientists are one step closer to using CRISPR gene editing on humans, with a US federal advisory panel approving the use of the technique for a study led by the University of Pennsylvania.

The scientists are seeking to use the CRISPR-Cas9 technique to create genetically altered T cells – white blood cells that play an important role in our immune system – that are more effective at fighting cancer cells in patients with melanoma, multiple myeloma, and sarcoma.

“Our preliminary data suggests that we could improve the efficacy of these T cells if we use CRISPR,” lead researcher Carl June told the National Institute of Health’s (NIH) Recombinant DNA Advisory Committee (RAC) on Tuesday.

Read more

Washington University in St. Louis and Keio University in Japan is set to test the effectiveness and safety of the compound. Starting next month, about 10 healthy people will be administered NMN to see if can improve bodily function and stave off the effects of aging. Should it work, it would become the first bona fide anti-aging intervention available on the market.

A compound called nicotinamide mono nucleotide (NMN) has been shown to slow down the aging process and extend the lifespans of mice. We’re about to find out if it does the same thing to humans.

A planned clinical trial devised by researchers from Washington University in St. Louis and Keio University in Japan is set to test the effectiveness and safety of the compound. Starting next month, about 10 healthy people will be administered NMN to see if can improve bodily function and stave off the effects of aging. Should it work, it would become the first bona fide anti-aging intervention available on the market.

Read more

Want to fight aging; eat this new chocolate.

Cambridge UK (PRWEB UK) 19 June 2016 Lycotec Ltd., a biotech company based in Cambridge UK, http://www.lycotec.com announces that they have developed the World’s First Longevity SIRT Chocolate, which after ingestion provides a blood level of unmodified trans-Resveratrol, t-RSV, equal to its level after drinking red wine.

T-RSV is the molecule of plant polyphenol class which is typically present in red grapes, some berries, cocoa and nuts. There are a number of beneficial health effects of t-RSV from cardioprotective to antidiabetic. However, one of its intriguing properties is the ability to activate a group of SIRT genes. These genes are responsible for controlling cellular stress protection and longevity.

When t-RSV is consumed as part of food, or a beverage, or as an isolated extract in the form of most supplements, it quickly gets modified and inactivated in the digestive tract. Drinking red wine is the only known exception when t-RSV can reach the blood in an unmodified active form at a detectable level.

Read more

Sperm have been made in the laboratory and used to father healthy baby mice in a pioneering move that could lead to infertility treatments.

The Chinese research took a stem cell, converted it into primitive sperm and fertilised an egg to produce healthy pups.

The study, in the Journal Cell Stem Cell, showed they were all healthy and grew up to have offspring of their own.

Read more